Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Olvi-Vec

Phase 2Small molecule

NNewsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.

Olvi-Vec is one of 7 small molecule programs targeting SCLC. It is currently in Phase 2.

1

Indications

1

Total Trials

1

Active Trials

6

Competitors

Pipeline

Status by Indication[3][1]

Indication

SCLCRecruiting

SCLCPhase 2

Recruiting

Competition

Competitive Landscape

7 competitors in SCLC

#DrugCompanyPhaseTrials

Vepesid

Platinum

Bristol-Myers Squibb

Tecentriq

Serplulimab

Shanghai Henlius Biotech

Paraplatin

Olvi-Vec

NNewsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.

ZL-1310

ZZai Lab (Shanghai) Co., Ltd.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

SCLC

NCT07136285

Clinical

Trials by Indication[1]

SCLC1 trial

Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC

Recruiting·NNewsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.·Phase 1/2·NCT07136285·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Olvi-Vec. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Olvi-Vec compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Olvi-Vec. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNewsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.

Related News